Incannex Healthcare Inc. (IXHL)

Market Cap	42.12M +1,257.8%
Revenue (ttm)	n/a +616.7%
Net Income	-48.41M
EPS	-5.22
Shares Out	11.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	127,325
Open	3.640
Previous Close	3.640
Day's Range	3.510 - 3.710
52-Week Range	2.490 - 49.800
Beta	2.95
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About IXHL

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: IXHL
• Website: https://www.incannex.com

Financial Performance

In fiscal year 2025, Incannex Healthcare's revenue was $86,000, an increase of 616.67% compared to the previous year's $12,000. Losses were -$46.89 million, 154.0% more than in 2024.